🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Placebo for TMC435

Found 14 matching trials

TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light

PHASE1

The purpose of the study is to evaluate the potential effect of TMC435 on t...

Status

Completed

Location

Multiple Locations

Start Date

2010-07

Trial ID

NCT01124799

Treatments Being Tested

TMC435 Placebo Ciprofloxacin

TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers

PHASE1

The purpose of this study is to evaluate the safety and tolerability of thr...

Status

Completed

Location

Multiple Locations

Start Date

2008-08

Trial ID

NCT00752544

Treatments Being Tested

TMC435350

An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

PHASE3

The purpose of this study is to investigate the effectiveness and safety of...

Status

Completed

Location

Multiple Locations

Start Date

2011-02

Trial ID

NCT01281839

Treatments Being Tested

TMC435 Placebo Peginterferon alpha-2a (PegIFN alpha-2a)Ribavirin (RBV)

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants

PHASE3

The purpose of this study is to investigate the effectiveness and safety of...

Status

Completed

Location

Multiple Locations

Start Date

2011-03

Trial ID

NCT01290679

Treatments Being Tested

Placebo TMC435 Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)Ribavirin (RBV)

Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

PHASE2

Parts A and B of this study are designed to evaluate the safety, tolerabili...

Status

Completed

Location

Multiple Locations

Start Date

2013-03

Trial ID

NCT01852604

Treatments Being Tested

Samatasvir Simeprevir Ribavirin (RBV)TMC647055 Ritonavir (RTV)Pegylated interferon (Peg-IFN)Samatasvir matching placebo

A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

PHASE3

The purpose of this study is to investigate the efficacy of a treatment wit...

Status

Completed

Location

Multiple Locations

Start Date

2011-12

Trial ID

NCT01323244

Treatments Being Tested

TMC435

TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

PHASE1

The purpose of this study is to evaluate the effect of TMC435 on the result...

Status

Completed

Location

Multiple Locations

Start Date

2011-01

Trial ID

NCT01269294

Treatments Being Tested

TMC435 Placebo for TMC435 TMC435 Placebo for TMC435 Moxifloxacin Placebo for moxifloxacin Placebo for TMC435

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy

PHASE3

The purpose of this study is to demonstrate the efficacy of TMC435 in combi...

Status

Completed

Location

Multiple Locations

Start Date

2012-02

Trial ID

NCT01485991

Treatments Being Tested

TMC435 TVR

A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

PHASE3

The purpose of this study is to evaluate the efficacy and safety of TMC435 ...

Status

Completed

Location

Multiple Locations

Start Date

2011-02

Trial ID

NCT01292239

Treatments Being Tested

Placebo TMC435 Peginterferon alfa-2a (pegIFN alfa-2a)Ribavirin (RBV)

A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection

PHASE2

The purpose of this study is to investigate how efficient TMC435350 will wo...

Status

Completed

Location

Multiple Locations

Start Date

2008-01

Trial ID

NCT00561353

Treatments Being Tested

TMC435 Placebo Peginterferon (PegIFNα-2a)Ribavirin

Previous Next